12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Company News  |  Deals

Edict Pharmaceuticals, Par Pharmaceutical deal

Par completed its acquisition of generics company Edict for $20.5 million, plus $4.4 million for the repayment...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >